Carreadores lipídicos nanoestruturados contendo óleo de urucum (Bixa orellana L.): uma alternativa para o tratamento da leishmaniose cutânea

• Ano de defesa: 2018
• Autor(a) principal: Ferreira, Marianna Araújo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Brasil; UFRN; PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS FARMACÊUTICAS
• Palavras-chave em Português: Carreadores lipídicos nanoestruturados; Bixa orellana L.; Leishmaniose cutânea; CNPQ::CIENCIAS DA SAUDE::FARMACIA
• Link de acesso: https://repositorio.ufrn.br/jspui/handle/123456789/27433

Leishmaniasis is one of the leading Neglected Tropical Diseases (NTD). Every year millions of people are infected, however the drugs used have many adverse effects and low effectiveness. In this way the development of therapeutics alternatives becomes necessary. Nanotechnology has been outstanding for presenting efficient solutions in the development of new medicines. For this reason, the objective of this work was to incorporate the oily fraction of annatto (Bixa orellana L.), a vegetal active with proven action against parasites of the genus Leishmania, to Nanostructured Lipid Carriers (NLC). The nanoparticles were produced by the melt-emulsification method and were characterized in terms of particle size, polydispersity index, morphology, zeta potential, storage stability, encapsulation efficiency, thermal degradation profile, crystalline profile, in vitro cytotoxicity, antileishmania activity in vitro and evaluation of the influence of 3% (w/w) of synthetic Laponite® clay on the system. Analysis of the results showed the effectiveness of the production method, with nanoparticles ranging between 173.73 nm ± 1.15 and 185.23 nm ± 1.80, polydispersity of less than 0.3 and zeta potential between -23.07 mV ± 0.15 and -39.13 mV ± 0.50 and and stability during the storage time, even with the presence of Laponite® . The mass loss of the formulations occurred only at high temperatures (≅ 200°C). The crystalline structure of the nanocarriers promoted the encapsulation of 78.92 ± 2.89 and 52.54 ± 3.41 in the formulations with 2% and 4% of urucum oil, respectively. Carriers presented antileishmania activity similar to amphotericin B and greater than Glucantime® and unencapsulated annatto oil. These results demonstrate a stable system with proven biological activity and should, therefore, be seen as a therapeutic alternative for the treatment of cutaneous manifestations of leishmaniasis.